For the quarter ending 2025-09-30, PTIX had $2,788,067 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -5,927,019 |
| Amortization of debt discount to interest expense | 243,353 |
| Stock based compensation | 230,995 |
| Derivative expense | -343,399 |
| Change in fair value of derivative liabilities | -1,930,245 |
| Depreciation expense | 25,143 |
| Increase in note payable for acquisition of phytanix bio | 583,880 |
| Inventories | 37 |
| Prepaid expenses | 3,838 |
| Vat receivable | -29,481 |
| Accounts payable | -177,180 |
| Accrued liabilities | 158,912 |
| Net cash used in operating activities | -2,562,666 |
| Cash received in acquisition of phytanix bio | -943,180 |
| Net cash provided by investing activities | 943,180 |
| Proceeds from sale of common stock | 395,474 |
| Proceeds from exercise of warrants | 3,949,732 |
| Proceeds from related party loans | 62,347 |
| Net cash provided by financing activities | 4,407,553 |
| Net increase in cash | 2,788,067 |
| Effect of exchange rate changes on cash | -80,147 |
| Cash and cash equivalents at beginning of period | 14,531 |
| Cash and cash equivalents at end of period | 2,722,451 |
Protagenic Therapeutics, Inc. new (PTIX)
Protagenic Therapeutics, Inc. new (PTIX)